Exelixis Inc (NASDAQ: EXEL) has seen a decline in its stock price by -0.03 in relation to its previous close of 37.72. However, the company has experienced a 3.71% gain in its stock price over the last five trading sessions. businesswire.com reported 2025-03-25 that ALAMEDA, Calif.–(BUSINESS WIRE)–Exelixis, Inc. (Nasdaq: EXEL) today announced that preclinical data will be presented for four pipeline molecules at the American Association for Cancer Research (AACR) Annual Meeting 2025 taking place April 25-30 in Chicago, IL. “We are excited to share preclinical data from four of our pipeline molecules that constitute the next phase in our commitment to the discovery and development of innovative cancer treatments,” said Dana T. Aftab, Ph.D., Executive Vice.
Is It Worth Investing in Exelixis Inc (NASDAQ: EXEL) Right Now?
Exelixis Inc (NASDAQ: EXEL) has a higher price-to-earnings ratio of 21.28x compared to its average ratio, The 36-month beta value for EXEL is at 0.57. Analysts have varying views on the stock, with 7 analysts rating it as a “buy,” 5 rating it as “overweight,” 10 as “hold,” and 0 as “sell.”
The public float for EXEL is 271.82M, and currently, shorts hold a 4.89% of that float. The average trading volume for EXEL on March 26, 2025 was 2.63M shares.
EXEL’s Market Performance
EXEL’s stock has seen a 3.71% increase for the week, with a 1.56% rise in the past month and a 11.97% gain in the past quarter. The volatility ratio for the week is 2.64%, and the volatility levels for the past 30 days are at 2.89% for Exelixis Inc The simple moving average for the last 20 days is 0.17% for EXEL stock, with a simple moving average of 25.48% for the last 200 days.
Analysts’ Opinion of EXEL
Many brokerage firms have already submitted their reports for EXEL stocks, with Wells Fargo repeating the rating for EXEL by listing it as a “Equal Weight.” The predicted price for EXEL in the upcoming period, according to Wells Fargo is $36 based on the research report published on February 24, 2025 of the current year 2025.
Morgan Stanley, on the other hand, stated in their research note that they expect to see EXEL reach a price target of $40, previously predicting the price at $30. The rating they have provided for EXEL stocks is “Overweight” according to the report published on January 27th, 2025.
EXEL Trading at 5.65% from the 50-Day Moving Average
After a stumble in the market that brought EXEL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -5.77% of loss for the given period.
Volatility was left at 2.89%, however, over the last 30 days, the volatility rate increased by 2.64%, as shares surge +2.14% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +4.69% upper at present.
During the last 5 trading sessions, EXEL rose by +3.71%, which changed the moving average for the period of 200-days by +71.72% in comparison to the 20-day moving average, which settled at $37.64. In addition, Exelixis Inc saw 13.24% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at EXEL starting from Haley Patrick J., who sale 10,000 shares at the price of $38.80 back on Mar 03 ’25. After this action, Haley Patrick J. now owns 341,028 shares of Exelixis Inc, valued at $388,000 using the latest closing price.
PATRICK JOSEPH HALEY, the Officer of Exelixis Inc, proposed sale 10,000 shares at $38.80 during a trade that took place back on Mar 03 ’25, which means that PATRICK JOSEPH HALEY is holding shares at $388,000 based on the most recent closing price.
Stock Fundamentals for EXEL
Current profitability levels for the company are sitting at:
- 0.28 for the present operating margin
- 0.96 for the gross margin
The net margin for Exelixis Inc stands at 0.24. The total capital return value is set at 0.24. Equity return is now at value 23.13, with 17.42 for asset returns.
Based on Exelixis Inc (EXEL), the company’s capital structure generated 0.08 points at debt to capital in total, while cash flow to debt ratio is standing at 3.67.
Currently, EBITDA for the company is 718.75 million with net debt to EBITDA at -0.04. When we switch over and look at the enterprise to sales, we see a ratio of 4.85. The receivables turnover for the company is 8.17for trailing twelve months and the total asset turnover is 0.74. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.63.
Conclusion
In conclusion, Exelixis Inc (EXEL) has had a better performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
